The combination of surgery and chemotherapy is a hallmark of the management of ovarian cancer.1 Although surgery is an integral component of management of this disease, its role in recurrent disease has been a topic of debate. After the collection of decades of data from retrospective studies,2 the results of prospective, randomized trials to guide management are now becoming available. In this issue of the Journal, Harter et al.3 report the results of the Descriptive Evaluation of Preoperative Selection Criteria for Operability in Recurrent Ovarian Cancer (DESKTOP) III trial, a randomized, phase 3 trial that evaluated secondary cytoreductive surgery in . . .
No takes yet. Share an insight, caveat, or question.
A 2021 study studied this question.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: